Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation products and their uses.

S S Shord1, C M Lindley

  • 1Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360, USA. celeste_lindley@unc.edu

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|August 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Optimizing chemotherapy: concomitant medication lists.

Clinical pharmacology and therapeutics·2010
Same author

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.

Journal of clinical pharmacy and therapeutics·2009
Same author

Cytochrome P450 2C9 mediated metabolism in people with and without cancer.

International journal of clinical pharmacology and therapeutics·2008
Same author

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

Clinical pharmacology and therapeutics·2006
Same author

Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.

Drug metabolism and disposition: the biological fate of chemicals·2001
Same journal

Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

This review covers coagulation products for hemophilia, von Willebrand

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Patients with hemophilia, von Willebrand's disease (VWD), or acquired inhibitors to antihemophilic factor (AHF) require therapeutic interventions to manage acute hemorrhages.
  • A range of coagulation products are available, including AHF concentrates, factor IX concentrates, factor VIIa concentrate, factor IX complexes, anti-inhibitor coagulant complexes, and desmopressin acetate.

Purpose of the Study:

  • To review the indications, pharmacokinetics, and therapeutic guidelines for available coagulation products.
  • To guide product selection, dosing, and treatment duration for managing bleeding disorders.

Main Methods:

  • Review of existing literature on coagulation products.
  • Analysis of product indications, pharmacokinetics, and therapeutic guidelines.
  • Consideration of patient-specific factors, product purity, and viral attenuation.

Related Experiment Videos

Main Results:

  • Coagulation products are essential for managing acute bleeding and preventing surgical hemorrhage in patients with bleeding disorders.
  • Dosage and duration of therapy are influenced by hemorrhage severity, product pharmacokinetics, and individual patient factors.
  • Recombinant factor versions mitigate viral transmission risks.

Conclusions:

  • A comprehensive understanding of coagulation products is crucial for effective patient management.
  • Optimizing product selection, dosing, and treatment duration improves outcomes and minimizes risks like viral transmission.